Chondrosarcoma – Pipeline Review, 2019

Chondrosarcoma is among the rare types of bone cancer primarily affecting the cartilage producing cells at various anatomical locations including skull, pelvis, and hips. There are various types of chondrosarcomas depending upon the location. Chondrosarcoma is a combined term for a congregation of tumors that comprise of the ligament. These tumors include tumors with the low metastatic potential to high-review, aggressive tumors described by early metastasis. Around 30% of skeletal system cancers are chondrosarcomas.

There are various treatment methods currently available to treat chondrosarcoma. Among these, surgery is the main form of treatment for chondrosarcoma. Radiation therapy and chemotherapy are some of the other treatment methods for the treatment of chondrosarcoma. Chondrosarcoma is also treated with the combination of chemotherapy drugs such as vincristine (Oncovin), doxorubicin (Adriamycin) and cyclophosphamide (Procytox).

Research institutes are focusing on studying and developing new options for the treatment or prevention of chondrosarcoma. For instance; AG-120, which is being studied by Agios Pharmaceuticals, Inc., is currently in phase-1 clinical trials for the study of orally administered AG-120 in subjects with advanced solid tumors, including glioma, with an IDH1 mutation.

At present more than 50% of the pipeline candidates for chondrosarcoma are in phase 2. Majority of the studies are sponsored by research Institutes. 

Report Description

The report on ‘Chondrosarcoma – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Chondrosarcoma. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Chondrosarcoma.

The report on ‘Chondrosarcoma – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• A thorough assessment of the pipeline products by areas such as development stage; the route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences.

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases, 

Reasons to Buy this Report 

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Chondrosarcoma
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Chondrosarcoma
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive